DUMAC
VC Fund
Durham, United States
DUMAC is a VC fund in Durham focused on Medical and Biotechnology. DUMAC manages endowment funds and other investment funds. they invests in the public equity, fixed income and also invests in emerging markets. they invests in domestic, international, and emerging markets equity and hedge funds. Duke Management Company is located in Durham, North Carolina.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries DUMAC invests in
Stages DUMAC invests in
Countries DUMAC invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Marc Duey
|
|||
|
James B. Duke
|
|||
3 more contacts available
Investment Focus
Industry
- Medical 3 (38%)
- Biotechnology 3 (38%)
- Health Care 2 (25%)
- SaaS 1 (13%)
- Big Data 1 (13%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Seed 1 (13%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Country
- United States 6 (75%)
- China 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Marc Duey
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
|
James B. Duke
Founder
|
Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Archon Biosciences
|
Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management. | $20M / Seed / Oct 30, 2024 | |
Pryon
|
Pryon is an artificial intelligence company focused on enterprise knowledge management. Its natural language processing platform transforms unstructured data into experiences that increase productivity with unmatched accuracy and speed. Pryon’s automated machine learning engines deliver rapid time to value by enriching existing content. Thisno-code approach prevents operational disruption and allows organizations to quickly maximize the business value trapped within their information assets. Pryon was founded by Igor Jablokov, whose previous company defined the state of the art for AI assistants and was acquired by Amazon to form the basis for Alexa. | $12M / Nov 24, 2021 | |
|
Pryon
|
Pryon is an artificial intelligence company focused on enterprise knowledge management. Its natural language processing platform transforms unstructured data into experiences that increase productivity with unmatched accuracy and speed. Pryon’s automated machine learning engines deliver rapid time to value by enriching existing content. Thisno-code approach prevents operational disruption and allows organizations to quickly maximize the business value trapped within their information assets. Pryon was founded by Igor Jablokov, whose previous company defined the state of the art for AI assistants and was acquired by Amazon to form the basis for Alexa. | $12M / Venture - Series Unknown / Sep 27, 2021 | |
New Horizon Health
|
New Horizon Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancerscreening into thousands of households so that the public can enjoy convenient and efficient health services . | $66.5M / Series C / May 24, 2019 | |
Area 1 Security
|
Based in Redwood City, CA, Area 1 Security is developing a product focused on eliminating targeted, socially engineered cyber attacks. Founded by security experts from NSA and MIT, and data analytics specialists from NSA and Disney, the stealth mode startup has raised $25.5 million in total funding to date. Investors include Icon Ventures, KleinerPerkins Caufield & Byers, Allegis Capital, Cowboy Ventures; Data Collective (DCVC); First Round Capital; RedSeal Networks CEO and former Venrock partner Ray Rothrock; and Shape Security CEO Derek Smith. | $32M / Series A / Oct 23, 2018 | |
Precision BioSciences
|
Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editingtechnology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome. | $110M / Series B / Jun 08, 2018 | |
Managed by Q
|
Managed by Q makes it easy to run an office. Known as the operating system for offices, Q saves businesses and employees valuable time by providing a range of subscription and on-demand services, from cleaning and maintenance to supply replenishment and wellness. Today, the Managed by Q technology platform connects thousands of businesses to theservices required to seamlessly run their workspaces. The company is committed to spreading a mission of economic empowerment, by creating good jobs for its Operators and providing opportunities for small business to flourish. With operations in New York, Los Angeles, Chicago and San Francisco, Managed by Q is redefining the way the world works. | $25M / Series B / Apr 01, 2016 | |
Baebies
|
Baebies was founded in 2014 by Richard West and Vamsee Pamula, following the successful development of digital microfluidics technology, the development and launch of multiple products, and the eventual sale of Advanced Liquid Logic to Illumina, Inc. Baebies has now licensed its core technology, acquired product and manufacturing assets, and builtseasoned management and technical teams to pursue opportunities in newborn screening and near-patient diagnostic testing. Baebies newborn screening platform, SEEKER, is FDA authorized and CE marked. The FINDER and FINDER 1.5 platforms are CE marked and the FINDER 1.5 SARS-CoV-2 test received emergency use notification from the FDA. Baebies’ digital microfluidics technology is a recipient of multiple awards, including the coveted Disruptive Technology Award from AACC in their ‘search for the next innovative testing solution that will transform patient careBaebies' mission is to save lives and make lives better by bringing new technologies, new tests, and new hope to newborns, patients, and healthcare professionals worldwide. | $13M / Series A / Jun 17, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does DUMAC invest in?
DUMAC invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact DUMAC?
Public channels for DUMAC include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at DUMAC?
The team at DUMAC includes Marc Duey (Managing Partner) and James B. Duke (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
